Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Drugs for Terminally Ill Clear New Hurdle

By R&D Editors | March 26, 2014

A proposal to allow terminally ill people access to drugs that are still completing clinical trials cleared its first test in the Colorado Legislature on Tuesday.
 
The House Health, Insurance & Environment Committee voted 10-1 for the measure after it was amended to make clear that the experimenting patients, not their insurers, are responsible for health costs after taking experimental drugs.
 
“This is a bill about personal choice,” said one of the bill’s sponsors, Rep. Joann Ginal, D-Fort Collins.
 
The bill now awaits a vote by the full House.
 
So-called “Right To Try” proposals are pending in several states. The Goldwater Institute, a Phoenix-based libertarian think tank, has promoted the measure as a way to help terminally ill people who don’t have time to wait for years of clinical trials for new medications.
 
The legislation still requires doctors to sign off on the use of an investigational product.
 
The only vote against the measure came from Rep. Rhonda Fields, D-Aurora, who worried the insurance exemption could leave terminally ill without coverage even for health problems unrelated to the unapproved drugs.
 
“I’m concerned about the lack of insurance when someone is dying,” Fields said.
 
Another sponsor of the bill, Republican Rep. Janak Joshi, of Colorado Springs, insisted there need to be liability protections for hospitals and insurers.
 
“Patients will have to recognize that they’re responsible,” Joshi said.
 
Pharmaceutical companies are neutral on the measure, and experimental drugs used outside clinical trials won’t affect the drugs’ path to wider use, sponsors said Tuesday.
 
Similar “Right To Try” proposals are pending in legislatures in Arizona, Louisiana and Missouri.
 
Date: March 26, 2014
Source: Associated Press
Author: Kristen Wyatt

Related Articles Read More >

R&D 100 Winner Spotlight: Regenity’s RejuvaKnee brings first new meniscus repair option in years
R&D 100 Winner Spotlight: A closer look at Thermo Fisher Scientific’s trio of R&D 100 wins in 2025
MIT team uses mysterious cell structure to record genetic activity
This pocket-sized “laboratory” can detect food allergens in minutes
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE